scispace - formally typeset
A

Ana Barac

Researcher at Georgetown University

Publications -  158
Citations -  8236

Ana Barac is an academic researcher from Georgetown University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 30, co-authored 126 publications receiving 5347 citations. Previous affiliations of Ana Barac include MedStar Georgetown University Hospital & MedStar Washington Hospital Center.

Papers
More filters
Journal ArticleDOI

Assessing Heart Failure vs Lymphoma Treatment Risks and Benefits-It Takes Two to Tango.

Ana Barac
- 29 Mar 2023 - 
TL;DR: The JAMA Cardiology journal published by the American Medical Association (AMA) as mentioned in this paper is the most widely cited journal in the field of Cardiology and has a large number of publications.
Journal ArticleDOI

Heart Failure Risk Prediction in Childhood Cancer Survivors: Where Is Our Crystal Ball?

TL;DR: A study derived and tested a new prediction model for the risk of heart failure among survivors of childhood cancer and uses logistic regression to identify the strongest predictors of CHF in young cancer survivors.
Journal ArticleDOI

Digital Technologies in Cardiac Rehabilitation: A Science Advisory From the American Heart Association

TL;DR: The American Heart Association science advisory was assembled to guide the development and implementation of digital cardiac rehabilitation interventions that can be translated effectively into clinical care, improve health outcomes, and promote health equity as mentioned in this paper .
Journal ArticleDOI

Abstract 11850: Association Between SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Antineoplastic Therapy Associated Cardiomyopathy and Heart Failure

TL;DR: In this paper , a retrospective cohort analysis was performed on de-identified, aggregate patient data from the TriNetX research network, where patients ≥ 18 years of age with a history of exposure to potentially cardiotoxic antineoplastic therapy between Jan 1, 2013 and Apr 30, 2020 who subsequently developed cardiomyopathy or heart failure and treated with guideline directed medical therapy (GDMT) were identified.